Sign in

CIK 0001231457

  • Non-accelerated filer
  • Smaller reporting company
  • Emerging growth company

GENELUX Corp

Sign in to watch
Ticker
GNLX
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
FY end
Dec 31
Incorporated
DE
Entity type
Operating
Phone
+1 805-267-9889
Business address
2625 TOWNSGATE ROAD, SUITE 230, WESTLAKE VILLAGE, CA, 91361
  1. 4 Planned sale Director sold 10,000 shares at $2.98 ($29,801)
  2. 4 Open-market sale Chief Scientific Officer sold 605 shares at $2.97 ($1,798)
  3. 4 Open-market sale Chief Technical Officer sold 605 shares at $2.97 ($1,799)
  4. 4 Open-market sale President and CEO sold 2,798 shares at $2.94 ($8,226)
  5. 4 Open-market sale Head of Regulatory sold 270 shares at $2.98 ($804)
  6. 4 Open-market sale Head of Regulatory sold 585 shares at an average $2.46 ($1,437)
  7. 4 Open-market sale Chief Technical Officer sold 906 shares at $2.42 ($2,193)
  8. 4 Open-market sale SVP, Clinical Development sold 906 shares at $2.42 ($2,193)
  9. 4 Open-market sale President and CEO sold 3,582 shares at $2.42 ($8,668)
  10. 4 Planned sale Director sold 10,000 shares at $2.90 ($28,957)
  11. 4 Derivatives Options or other derivatives
  12. 3 Insider Initial Statement of Ownership
  13. 4 Open-market sale SVP, Clinical Development sold 4,192 shares at an average $3.82 ($16,032)
  14. 4 Open-market sale President and CEO sold 17,182 shares at an average $3.86 ($66,370)
  15. 4 Open-market sale Chief Technical Officer sold 3,706 shares at an average $3.88 ($14,361)
  16. 4 Open-market sale Head of Regulatory sold 2,332 shares at an average $3.75 ($8,740)
  17. 4 Planned sale Director sold 10,000 shares at $5.00 ($50,008)
  18. 4 Derivatives Options or other derivatives
  19. 4 Derivatives Options or other derivatives
  20. 4 Grant or award Head of Regulatory acquired 10,000 shares (grant or award)

Page 2 of 10 · 190 filings